GLP-1
Driven by soaring demand for its diabetes and weight loss drugs, Novo Nordisk on Wednesday reported better-than-expected full-year 2023 earnings with a 31% sales increase.
Excluding its COVID-19-products Comirnaty and Paxlovid, Pfizer’s revenue in the fourth quarter of 2023 grew 8%. The company projects full-year revenue in 2024 to remain about flat.
Stringent regulation, manufacturing costs and absence of price control contribute to high GLP-1 agonist costs in the U.S. Patients could go to other countries for cheaper treatment.
The persistent shortage of genuine glucagon-like peptide 1 receptor agonist products has led to an increase in fake versions, the World Health Organization warned on Monday.
More than 3,000 people in the U.S. suffered from side effects of Ozempic in 2023, according to exclusive reporting on Wednesday from Reuters citing data from America’s Poison Centers.
As JPM week draws close, Lilly CEO David Ricks talks about what he thinks is in store for the biopharma industry.
There seems to be decidedly positive sentiment regarding biopharma in 2024—perhaps a harbinger of things to come this year coming off a topsy-turvy 2023.
The agency nevertheless said that it could not definitively rule out a small risk of suicidal ideation associated with GLP-1 receptor agonists, and that it will continue evaluating the evidence.
As the second day of the 42nd J.P. Morgan Healthcare Conference dawned in San Francisco, experts from Boston Consulting Group, Merck, CVC and more provided their outlook on the year ahead.
BioSpace continues to bring you the latest news and industry developments from the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. Stay tuned!
PRESS RELEASES